FGP
SPRY icon

Freestone Grove Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Freestone Grove Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16 Sell
2
-28,001
-100% -$268K ﹤0.01% 940
2025
Q4 		$326K Sell
28,003
-124,194
-82% -$1.21M ﹤0.01% 647
2025
Q3 		$1.53M Buy
+152,197
New +$2.18M 0.01% 391
2025
Q1 		– Sell
-12,501
Closed -$132K – 773
2024
Q4 		$132K Buy
+12,501
New +$175K ﹤0.01% 552

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Freestone Grove Partners's SPRY Position: Q1 2026 in Review

Freestone Grove Partners reduced its ARS Pharmaceuticals (SPRY) stake by 100% in Q1 2026, selling an estimated $268K and leaving 2 shares worth $16. The position accounts for ﹤0.01% of the portfolio, ranked #940.

Freestone Grove Partners first reported a position in SPRY in Q4 2024 and has held it in 4 quarters since. The position peaked at $1.53M in Q3 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Freestone Grove Partners held 2 shares of ARS Pharmaceuticals worth $16 as of Q1 2026.
  • Freestone Grove Partners sold 28,001 ARS Pharmaceuticals shares in Q1 2026, an estimated $268K.
  • ARS Pharmaceuticals made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #940 holding.
  • Freestone Grove Partners first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • Freestone Grove Partners's ARS Pharmaceuticals position peaked at $1.53M in Q3 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.